ESR1 and breast cancer: Together, these findings firmly position PR as much more than a marker of ERα action in breast cancer, and our observations that both estrogen and progesterone play a role in the upregulation of growth factor receptor pathways suggest that PR targeting should be considered more closely as a partner in currently employed endocrine and ErbB-targeted therapies.